Concepedia

Genomic Aberrations in Lung Adenocarcinoma in Never Smokers

Bastien Job, Alain Bernheim, Michèle Beau‐Faller, Sophie Camilleri‐Broët, Philippe Girard, Paul Hofman, Julien Mazières, Saloua Toujani, Ludovic Lacroix, Julien Laffaire,

PLoS ONE · 2010 · 72 citations · 39 references

DOIFull text

Open access

Abstract

The present study has uncovered new aberrations containing cancer genes. The oncogene FUS is a candidate gene in the 16p region that is frequently gained in never smokers. Multiple genetic pathways defined by gains of MYC, deletions of RB1 and WRN or gains on 7p and 7q are involved in lung adenocarcinoma in never smokers.

References

39

Mutations of the BRAF gene in human cancer

Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.6K citations · Full text

, , +5

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

More powerful procedures for multiple significance testing

Yosef Hochberg, Yoav Benjamini · Statistics in Medicine · 1990 · 2.7K citations

, , +22